Description
Genferon Lite Pharmacodynamics
GENFERON® LITE is a combined preparation, the effect of which is due to the components included in its composition. It has local and systemic effects.
Recombinant human interferon alfa-2b, produced by Escherichia coli strain, into which by genetic engineering methods the human interferon alfa-2b gene was introduced, is the component of the preparation Genferon® Lite.
Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. Antiviral effect is mediated by activation of a number of intracellular enzymes that inhibit viral replication. Immunomodulatory effect is primarily manifested by strengthening the cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved by activation of CD8+ T-rollers, NK-cells (natural killer cells), increasing differentiation of B-lymphocytes and their production of antibodies, activation of monocytic-macrophage system and phagocytosis as well as increasing expression of molecules of the main histocompatibility complex of type I, which increases the possibility of recognition of infected cells by the cells of immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane provides their active participation in liquidation of pathological foci; besides, due to the influence of interferon, restoration of production of secretory immunoglobulin A is achieved. Antimicrobial effect is mediated by immune system reactions enhanced under the influence of interferon.
Taurine promotes normalization of metabolic processes and tissue regeneration, has membranostabilizing and immunomodulatory effects. As a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to pathological processes. Taurine helps to preserve the biological activity of interferon, increasing the therapeutic effect of the drug.
Indications
As a component of the complex therapy – for the treatment of acute respiratory viral infections and other infectious diseases of bacterial and viral etiology in children.
– As a component of complex therapy – for the treatment and prevention of recurrent episodes of acute respiratory viral infections in children aged 3 to 6 years.
– For treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women, against the background of prescribed and controlled by a physician specific therapy.
Contraindications
Individual intolerance to interferon and other substances that make up the
the drug.
Dosage and administration
- The drug may be used both vaginally and rectally. The method of administration, the dose and duration of course depend on the age and the specific clinical situation. In adults and children over 7 years old Genferon® Lite is administered in a dose of 250 000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug in a dose of 125,000 IU of interferon alfa-2b per suppository. In women who are 13-40 weeks pregnant, the drug is used in a dose of 250,000 IU of interferon alfa-2b per suppository.
- Recommended doses and treatment regimens:
● Acute respiratory viral infections and other acute diseases of viral nature in children: 1 suppository rectally 2 times daily at 12-hour intervals in parallel with basic therapy for 5 days. If at the end of the 5-day treatment period the symptoms of the disease are not reduced or become more pronounced, the patient should consult a physician. Repetition of treatment after the 5-day interval is possible for clinical indications. - Acute respiratory viral infections in ill children aged 3 to 6 years: 1 suppository (125,000 IU) rectally twice daily at 12-hour intervals for 10 days along with standard therapy. After completion of the main period of treatment of acute respiratory viral infection it is possible to switch to the prophylactic scheme: 1 suppository (125,000 IU) rectally 1 time per night every other day for 3 weeks.
- Chronic inflammatory infections of viral etiology in children over 7 years old: 1 suppository (250,000 IU) rectally 2 times a day at 12-hour intervals parallel to the standard therapy for 10 days. Then for 1-3 months, 1 suppository rectally at night every other day.
- Acute infectious-inflammatory diseases of the urogenital tract in children: 1 suppository rectally twice a day at 12-hour intervals for 10 days against the background of prescribed and controlled specific therapy.
- Infection and inflammatory diseases of the urogenital tract in pregnant women: 1 suppository (250,000 IU) vaginally twice a day at 12-hour intervals for 10 days against the background of a physician-prescribed and controlled specific therapy.
- Infectious inflammatory diseases of the urogenital tract in women: 1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day at 12-hour intervals for 10 days against the background of prescribed and controlled specific therapy. In prolonged forms 3 times a week, 1 suppository every other day for 1-3 months.
